Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2013, Article ID 650847, 7 pages
http://dx.doi.org/10.1155/2013/650847
Research Article

Haptoglobin Genotype and Risk Markers of Cardiovascular Disease in Patients with Chronic Kidney Disease

1Department of Nephrology, Aalborg Hospital, Aarhus University Hospital, Moelleparkvej 4, 9000 Aalborg, Denmark
2Center for Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
3Department of Nephrology, Aarhus University Hospital, 8200 Aarhus N, Denmark
4Department of Clinical Biochemistry, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark

Received 3 December 2012; Revised 19 January 2013; Accepted 3 February 2013

Academic Editor: Alejandro Martín-Malo

Copyright © 2013 Charlotte Strandhave et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. A. Herzog, J. M. Mangrum, and R. Passman, “Sudden cardiac death and dialysis patients,” Seminars in Dialysis, vol. 21, no. 4, pp. 300–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” American Journal of Kidney Diseases, vol. 32, no. 5, supplement 3, pp. S112–S119, 1998. View at Google Scholar · View at Scopus
  3. M. Kanbay, B. Afsar, D. Goldsmith, and A. Covic, “Sudden death in hemodialysis: an update,” Blood Purification, vol. 30, no. 2, pp. 135–145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. K. Cheung, M. J. Sarnak, G. Yan et al., “Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients,” Kidney International, vol. 58, no. 1, pp. 353–362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. M. G. Shlipak, L. F. Fried, M. Cushman et al., “Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors,” Journal of the American Medical Association, vol. 293, no. 14, pp. 1737–1745, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Locatelli, B. Canaud, K. U. Eckardt, P. Stenvinkel, C. Wanner, and C. Zoccali, “Oxidative stress in end-stage renal disease: an emerging treat to patient outcome,” Nephrology Dialysis Transplantation, vol. 18, no. 7, pp. 1272–1280, 2003. View at Google Scholar · View at Scopus
  7. European Task Force, “Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology,” Circulation, vol. 93, no. 5, pp. 1043–1065, 1996. View at Google Scholar
  8. K. Oikawa, R. Ishihara, T. Maeda et al., “Prognostic value of heart rate variability in patients with renal failure on hemodialysis,” International Journal of Cardiology, vol. 131, no. 3, pp. 370–377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. C. Longenecker, M. Zubaid, K. V. Johny et al., “Association of low heart rate variability with atherosclerotic cardiovascular disease in hemodialysis patients,” Medical Principles and Practice, vol. 18, no. 2, pp. 85–92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. M. Albert, J. Ma, N. Rifai, M. J. Stampfer, and P. M. Ridker, “Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death,” Circulation, vol. 105, no. 22, pp. 2595–2599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men,” The New England Journal of Medicine, vol. 336, no. 14, pp. 973–979, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Haverkate, S. G. Thompson, S. D. M. Pyke, J. R. Gallimore, and M. B. Pepys, “Production of C-reactive protein and risk of coronary events in stable and unstable angina,” The Lancet, vol. 349, no. 9050, pp. 462–466, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Bazeley, B. Bieber, Y. Li et al., “C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2452–2461, 2011. View at Google Scholar
  15. R. S. Parekh, L. C. Plantinga, W. H. L. Kao et al., “The association of sudden cardiac death with inflammation and other traditional risk factors,” Kidney International, vol. 74, no. 10, pp. 1335–1342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. R. Langlois and J. R. Delanghe, “Biological and clinical significance of haptoglobin polymorphism in humans,” Clinical Chemistry, vol. 42, no. 10, pp. 1589–1600, 1996. View at Google Scholar · View at Scopus
  17. P. M. Guéye, N. Glasser, G. Férard, and J. M. Lessinger, “Influence of human haptoglobin polymorphism on oxidative stress induced by free hemoglobin on red blood cells,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 5, pp. 542–547, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Smithies, “An improved procedure for starch-gel electrophoresis: further variations in the serum proteins of normal individuals,” The Biochemical Journal, vol. 71, no. 3, pp. 585–587, 1959. View at Google Scholar · View at Scopus
  19. S. M. Sadrzadeh and J. Bozorgmehr, “Haptoglobin phenotypes in health and disorders,” American Journal of Clinical Pathology, vol. 121, supplement, pp. S97–S104, 2004. View at Google Scholar · View at Scopus
  20. A. P. Levy, I. Hochberg, K. Jablonski et al., “Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study,” Journal of the American College of Cardiology, vol. 40, no. 11, pp. 1984–1990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Asleh and A. P. Levy, “In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease,” Vascular Health and Risk Management, vol. 1, no. 1, pp. 19–28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. Burbea, F. Nakhoul, R. Zoabi et al., “Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients,” Annals of Clinical Biochemistry, vol. 41, no. 6, pp. 469–473, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Pernod, J. L. Bosson, D. Golshayan et al., “Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort,” Kidney International, vol. 69, no. 8, pp. 1424–1430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. H. Christensen, H. B. Krarup, S. Riahi, E. Toft, and E. B. Schmidt, “Heart rate variability is associated with haptoglobin phenotype in patients with coronary artery disease,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 12, no. 3, pp. 221–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Delanghe, K. Allcock, M. Langlois, L. Claeys, and M. De Buyzere, “Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography,” Clinica Chimica Acta, vol. 291, no. 1, pp. 43–51, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Tamura, H. Tsuji, T. Nishiue, I. Yajima, T. Higashi, and T. Iwasaka, “Determinants of heart rate variability in chronic hemodialysis patients,” American Journal of Kidney Diseases, vol. 31, no. 4, pp. 602–606, 1998. View at Google Scholar · View at Scopus
  27. P. Stenvinkel, C. Wanner, T. Metzger et al., “Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?” Kidney International, vol. 62, no. 5, pp. 1791–1798, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Ramkumar, A. K. Cheung, L. M. Pappas, W. L. Roberts, and S. Beddhu, “Association of obesity with inflammation in chronic kidney disease: a cross-sectional study,” Journal of Renal Nutrition, vol. 14, no. 4, pp. 201–207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Carter and M. Worwood, “Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases,” International Journal of Laboratory Hematology, vol. 29, no. 2, pp. 92–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Galatius-Jensen, The Haptoglobins. A Genetical Study, Dansk Videnskabs Forlag, Copenhagen, Denmark, 1960.
  31. P. J. Schwartz, “The autonomic nervous system and sudden death,” European Heart Journal, vol. 19, pp. F72–F80, 1998. View at Google Scholar · View at Scopus
  32. R. Ranpuria, M. Hall, C. T. Chan, and M. Unruh, “Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV,” Nephrology Dialysis Transplantation, vol. 23, no. 2, pp. 444–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Chandra, R. L. Sands, B. W. Gillespie et al., “Predictors of heart rate variability and its prognostic significance in chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 27, no. 2, pp. 700–709, 2012. View at Google Scholar
  34. J. M. Huston and K. J. Tracey, “The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy,” Journal of Internal Medicine, vol. 269, no. 1, pp. 45–53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. J. Tracey, “Physiology and immunology of the cholinergic antiinflammatory pathway,” Journal of Clinical Investigation, vol. 117, no. 2, pp. 289–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. S. N. Psychari, L. Sinos, C. Iatrou, G. Liakos, and T. S. Apostolou, “Relations of inflammatory markers to lipid levels and autonomic tone in patients with moderate and severe chronic kidney disease and in patients under maintenance hemodialysis,” Clinical Nephrology, vol. 64, no. 6, pp. 419–427, 2005. View at Google Scholar · View at Scopus
  37. J. P. Chapelle, A. Albert, and J. P. Smeets, “Effect of the haptoglobin phenotype on the size of a myocardial infarct,” The New England Journal of Medicine, vol. 307, no. 8, pp. 457–463, 1982. View at Google Scholar · View at Scopus
  38. J. Delanghe, B. Cambier, M. Langlois et al., “Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery,” Atherosclerosis, vol. 132, no. 2, pp. 215–219, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. D. De Bacquer, G. De Backer, M. Langlois, J. Delanghe, H. Kesteloot, and M. Kornitzer, “Haptoglobin polymorphism as a risk factor for coronary heart disease mortality,” Atherosclerosis, vol. 157, no. 1, pp. 161–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Asaf, S. Blum, A. Roguin et al., “Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice,” Cardiovascular Diabetology, vol. 8, article 29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. P. Levy, M. G. Larson, D. Corey, R. Lotan, J. A. Vita, and E. J. Benjamin, “Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort,” Atherosclerosis, vol. 172, no. 2, pp. 361–365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Delanghe, M. Langlois, D. Duprez, M. De Buyzere, and D. Clement, “Haptoglobin polymorphism and peripheral arterial occlusive disease,” Atherosclerosis, vol. 145, no. 2, pp. 287–292, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Braeckman, D. De Bacquer, J. Delanghe, L. Claeys, and G. De Backer, “Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables,” Atherosclerosis, vol. 143, no. 2, pp. 383–388, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. J. R. Delanghe, D. A. Duprez, M. L. De Buyzere et al., “Haptoglobin polymorphism and complications in established essential arterial hypertension,” Journal of Hypertension, vol. 11, no. 8, pp. 861–867, 1993. View at Google Scholar · View at Scopus
  45. A. Mohieldein, M. Alzohairy, M. Hasan, and A. A. Khan, “Inflammatory markers and haptoglobin polymorphism in Saudi with non-insulin-dependent diabetes mellitus,” Global Journal of Health Science, vol. 5, no. 1, pp. 135–142, 2012. View at Google Scholar
  46. G. Pernod, J. L. Bosson, D. Golshayan et al., “The diamant alpin dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients,” Journal of Nephrology, vol. 17, no. 1, pp. 66–75, 2004. View at Google Scholar · View at Scopus
  47. A. N. N. Mertens and P. Holvoet, “Oxidized LDL and HDL: antagonists in atherothrombosis,” FASEB Journal, vol. 15, no. 12, pp. 2073–2084, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Brouwers, M. Langlois, J. Delanghe et al., “Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism,” Atherosclerosis, vol. 176, no. 1, pp. 189–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. A. P. Levy, J. E. Levy, S. Kalet-Litman et al., “Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 134–140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. C. J. Roche, D. Dantsker, A. I. Alayash, and J. M. Friedman, “Enhanced nitrite reductase activity associated with the haptoglobin complexed hemoglobin dimer: functional and antioxidative implications,” Nitric Oxide, vol. 27, no. 1, pp. 32–39, 2012. View at Publisher · View at Google Scholar
  51. J. T. Sertorio, R. Lacchini, L. M. Amaral et al., “Haptoglobin polymorphism affects nitric oxide bioavailability in preeclampsia,” Journal of Human Hypertension, 2012. View at Publisher · View at Google Scholar